Best of Show Contestants
(Submit Your Vote Here)
Alipheron | Pharos3D | Booth 509
https://alipheron.com
Our new software, Pharos3D, is currently the only 3D-analogue search tool capable of exhaustively searching ultra-large chemical spaces containing around 10^14 small molecules; four orders of magnitude beyond other exhaustive methods. Running on standard CPU-based server hardware, a typical search completes in approximately 6 hours. Integrating Pharos3D into early-stage drug discovery processes like 3D-based hit expansion and scaffold hopping increases the likelihood of readiness toward ADMET liabilities and enables a much broader IP protection.
Consensus | Consensus, Version: 2026 | Booth 427
https://consensus.app
Consensus is an AI research platform that helps life-science professionals find, evaluate, and synthesize scientific evidence faster. Built on more than 250 million peer-reviewed papers, it delivers citation-backed answers that trace every insight to its source.
Its research agent goes beyond traditional academic search by planning and executing multi-step workflows: breaking complex questions into targeted searches, applying scientific filters (study design, publication date, journal quality), and synthesizing findings across the literature. Where available, it analyzes full text from major publishers, including ACS, Wiley, Taylor & Francis, Sage, AAAS, and APA, rather than abstracts alone.
For drug-discovery and biomedical teams, Consensus accelerates literature intensive work such as evaluating emerging targets, investigating mechanisms of action, comparing experimental findings, identifying research gaps, and tracking new therapeutic approaches. Agentic search, rigorous source selection, full-text analysis, and verifiable citations together help researchers move from broad questions to evidence-grounded conclusions with greater speed and confidence.
Cube Biotech | PlateX MP™ Strep-Tactin®XT MagBeads | Booth 405
https://cube-biotech.com/products/membrane-protein-stabilization/screening-plates/platex-mp-strep-tactin-xt-magbeads/90860
PlateX MP™: Native Membrane Protein Purification, Automated
Membrane proteins, including GPCRs, ion channels, transporters, and receptor tyrosine kinases, account for roughly 60% of all druggable targets. Yet their embedding in the lipid bilayer makes them exceptionally hard to purify without losing the very properties a drug hunter needs to see.
Three bottlenecks slow membrane protein purification today. Manual handling is long, error-prone, and hard to scale. Every protein behaves differently, so screening for the right condition is essential and adds time. And traditional protocols rely on detergents that strip the native lipid environment, making the right solubilisation agent slow to find.
Cube Biotech's PlateX MP™ addresses all three at once. Built on proprietary copolymer-based NativeMP™ chemistry and run on liquid handling robots such as the CyBio FeliX, it screens for the optimal solubilisation condition and purifies membrane proteins in one automated workflow, without detergents, preserving native lipid environment, structure, and function.
In head-to-head testing across multiple GPCRs, automated NativeMP™ purification consistently delivered substantially higher yields than manual copolymer- or detergent-based purification, required far less starting cell biomass, and cut processing time from several working days to just two hours, a faster, more efficient, and scalable workflow.
The result: membrane proteins that are more stable, thermally robust, and functionally active, with native, accurate surface properties, giving researchers a reliable starting point for antibody discovery, small-molecule screening, and biologics engineering across pharmaceutical and biotech drug discovery programs.
DIMA Biotechnology LLC | PeptiNanodisc Full-length Multi-pass Transmembrane Recombinant Protein
https://www.dimabio.com/peptinanodisc-the-solution-for-membrane-protein-cell-assays
PeptiNanodisc™: A Breakthrough Lipid-Free Platform for Functional Membrane Protein Assays
PeptiNanodisc™ is a new peptide-based technology that transforms full-length membrane proteins into soluble, stable, assay-ready reagents without the lipid bilayer used in conventional nanodiscs. Specially designed synthetic peptides replace detergent around hydrophobic transmembrane regions, stabilizing full-length membrane proteins while maintaining native-like structure and functional antigen presentation.
What is new in this release?
PeptiNanodisc introduces a lipid-free, peptide-scaffold format specifically engineered to overcome a major limitation of conventional membrane-protein technologies: incompatibility with cell-based assays caused by detergents or lipid-mediated membrane fusion/interference. This enables functional full-length membrane proteins to be used directly in cellular applications—including highly specific CAR-T positivity detection where conventional nanodiscs are difficult to apply.
Technical specifications:
PeptiNanodisc proteins are produced in HEK293 cells and offered as full-length human membrane proteins with C-terminal Flag, Strep, or Avi tags, including biotinylated and FITC-labeled formats. The platform supports diverse membrane protein classes, including complex multi-pass proteins. Functional activity has been validated by ELISA and cell-based assays. CLDN18.2 and GPRC5D PeptiNanodiscs demonstrated CAR positivity detection comparable to established controls, while FITC-labeled CLDN18.2 PeptiNanodisc enabled direct detection without a fluorescent secondary antibody. Lyophilized products maintain binding activity and protein integrity, supporting ambient-temperature shipping.
PeptiNanodisc turns challenging membrane proteins into practical, functional tools for cell-based research and drug discovery.
Inductive Bio | Inductive's Virtual Lab, inclusive of Compass and Indy | Booth 428
https://www.inductive.bio/
Inductive Bio's virtual chemistry lab lets drug hunters test design ideas computationally before committing synthetic resources.
Compass runs thousands of compounds per design cycle through ADMET, PK, FEP and cofolding models, integrating competing parameters into a projected human dose and its uncertainty. Teams optimize against dose, the metric that decides whether a molecule becomes a drug, and deprioritize analogs unlikely to be viable. The underlying Beacon models draw on a pre-competitive ADMET consortium, fine-tuned to each program's chemical space, retrained weekly on incoming SAR, expert-QC'd, and integrated via REST API and MCP. Beacon took first in three consecutive blind ADMET benchmarking challenges against more than 750 competitors, including large pharma and frontier AI labs.
New in this release: Indy, an AI chemistry assistant. Indy takes on the work that consumes medicinal chemists' time but not their creativity. It QCs assay data as it lands, flagging outliers, discordant replicates and curve-fit failures before a bad number reaches a design decision. It runs matched molecular pair analysis across a full series and builds the leaderboard figures. It enumerates rational analogs weighted by synthetic tractability and reagent availability. It keeps the synthesis queue current against your ELN, extracts results from CRO decks, and assembles the weekly update.
On 84 dose-response curves from live programs, Indy caught 91% of known quality issues. General-purpose frontier agents caught 33-54%, missing every nonzero baseline and improper Hill slope even when handed a checklist. Indy learned from working drug hunters, not a general model of chemistry.
lino Biotech AG | MACS Matchmaker Polyreactivity Panel, Essentials 8-plex and Plus 16-plex | Booth 407
https://www.lino-biotech.com/applications/polyreactivity-panel
The MACS Matchmaker Polyreactivity Panel is a ready-to-use multiplexed ligand set. It quantifies non-specific binding on the same chip, the same sample, and the same run as target binding kinetics. Introduced in May 2026, it extends the MACS Matchmaker from single-ligand adapters to pre-conjugated multi-ligand panels.
Polyreactivity drives clinical attrition through fast serum clearance, immunogenicity, and aggregation. Today it is measured off-instrument. PSR-ELISA, AC-SINS, and BV-ELISA each take hours per plate and consume tens of micrograms of candidate. All three run on different hardware than the affinity assay. Polyreactivity therefore gets measured late, on a short list, after a lead has often already been committed.
The panel runs inside the same experiment. It immobilizes defined ligands by DNA-directed immobilization (DDI) on a Ta2O5 waveguide sensor. One label-free injection reads every liability axis in roughly 30 minutes per candidate, in picograms per square millimeter of directly measured bound mass. The resulting Polyreactivity Index is anchored to the Jain 2017 clinical-stage benchmark of 137 monoclonal antibodies. It therefore gives a calibrated risk score that can be compared across candidates.
Two configurations are available. Essentials covers eight liability axes with eight within-chip replicates each, built for triage at every discovery cycle. Plus covers sixteen axes with four replicates each, built for lead nomination and IND-enabling work. Both are pre-conjugated through a single NHS chemistry, with no aggregates, no membrane preparations, and no carrier-protein conjugates.
LiteFold | LiteMol-1 | Booth 508
https://www.litefold.ai/research/litemol1
LiteMol-1 is a masked diffusion language model trained from scratch on molecular sequence tokens. One set of weights covers classes usually handled by separate specialists: small molecules, linear and cyclic peptides, non-canonical and depsipeptides, macrocycles, and PROTACs. Generation is absorbing-state discrete diffusion over SMILES — training progressively masks tokens, inference denoises a fully masked string into a molecule. A structure-aware masking schedule exposes bond and scaffold tokens to corruption later, biasing generation toward scaffold-first construction. Conditional and unconditional generation train in the same network, so classifier-free guidance controls how strongly a sample follows a protein target.
The central claim concerns interface, not just performance. Sequence is compact and editable, letting the model sit inside an agent's generate–inspect–simulate–evaluate–edit loop, with structure tools reserved for verifying a small candidate set. Monte Carlo Tree Search over reverse diffusion handles multi-objective design, keeping a Pareto non-dominated set rather than one weighted score.
On twelve peptide targets, AF3 co-fold ipSAE is competitive with RFdiffusion3, BoltzGen and O-Design, generated on a single L40S in a workflow five to six times faster. MCTS lifts peptide validity from 0.77 to 0.98 and small-molecule validity to 1.00 without collapsing diversity. Protein-conditioned docking reaches 8.02 against ProtoBind-Diff's 8.17, and LiteMol-1 + MCTS leads the joint QED/retrieval/docking picture shown on the poster. Frozen embeddings recover chemistry better than Uni-Mol or Morgan on all five tested properties.
mcule.com Kft | Mcule SynthAgora | Booth 303
https://synthagora.mcule.com/
Mcule SynthAgora - The first chemical CRO marketplace
Move from the current FTE-based model to a fee-for-service approach and pay only for successfully synthesized compounds! Access the diverse chemical knowledge and resources of 50+ well-established chemical CRO partners through a single a platform! With Mcule Synthagora, you can launch reverse auctions to collect synthesis offers from chemistry partners competing on quality, lead time and price. As the first dedicated chemical CRO marketplace, Mcule Synthagora provides a centralized point of service ensuring scalability, transparency and true market-driven competition to support your medicinal chemistry projects.
Key features of Mcule SynthAgora
- Unified platform of 50+ well-established CROs
- Order custom synthesis in Fee-for-Service (FFS) model
- Free to access
- Scale up / down your custom synthesis needs seamlessly
- Pay only for successful syntheses
- Reduce synthesis time & cost while increasing success rate by market-driven competition
- Single point of contact for 50+ chemical CRO partners offering diverse knowledge and capabilities
- Handpick the ideal CRO for each project
- Easily combine and cherry-pick offers from multiple CROs
- Transparent legal framework including an exclusivity clause
- Track all your synthesis requests, offers, and orders via a single platform
OpenEye, Cadence Molecular Sciences | Target X | Booth 416
https://www.eyesopen.com/targetx
Target X™ — The Gold Standard for Target Exploration
Target X is a first‑in‑class target exploration solution that transforms proteins from static structures into dynamic, druggable landscapes. By combining enhanced molecular dynamics, pocket detection, and rigorously validated AI-enhanced ligandability prediction, Target X enables confident discovery and prioritization of cryptic, transient, and allosteric binding sites, and expansion of known pockets, including on historically undruggable targets.
At its core, Target X employs weighted ensemble molecular dynamics (WE‑MD) guided by intrinsic protein motions to efficiently sample rare but therapeutically meaningful conformations. Single‑ and mixed‑solvent simulations with probe occupancy analysis reveal emergent binding sites spanning local fluctuations and large‑scale rearrangements. Identified pockets are then quantitatively ranked with AI using a ligandability model trained on 1,847 non‑redundant binding pockets, curated using true 3D pocket similarity to eliminate bias and data leakage. This approach delivers 91% accuracy, 97% precision, and correct identification of 81% of FDA‑approved drug binding sites, with >90% success in detecting known cryptic pockets from apo structures alone.
Target X supports two independent workflows: ligandability ranking of MD‑derived pockets or direct scoring of static protein structures, enabling immediate use at any project stage. Delivered as a fully automated, end‑to‑end workflow on the cloud‑native Orion® Molecular Design Platform, Target X scales across hundreds to thousands of GPUs and produces pocket geometries ready for virtual screening and structure‑based design.
By uniting physics‑based dynamics, unbiased AI, and massive cloud scalability, Target X sets a new best‑in‑class standard for early‑stage target exploration.
ORIA Bioscience | LYSO-Prep™ | Booth 425
https://oriabs.com/product/lyso-prep/
𝐋𝐘𝐒𝐎-𝐏𝐫𝐞𝐩™ – 𝐑𝐞𝐚𝐝𝐲-𝐭𝐨-𝐮𝐬𝐞 𝐢𝐬𝐨𝐥𝐚𝐭𝐞𝐝 𝐥𝐲𝐬𝐨𝐬𝐨𝐦𝐞𝐬 𝐩𝐫𝐞𝐩𝐚𝐫𝐚𝐭𝐢𝐨𝐧𝐬 𝐟𝐨𝐫 𝐇𝐓𝐒
LYSO-Prep™ is the first industrial-grade, ready-to-use preparation of entire, functional lysosomes for drug discovery. Using our patented microfluidic technology, ORIA Bioscience isolates millions of intact lysosomes per hour directly from cells, preserving native membrane proteins and enzymatic activity, with over 90% purity and over one-month frozen storage stability.
What's new: LYSO-Prep™ is now available across a growing portfolio of cell backgrounds (including HEK293 and iPSC-derived lines) and target configurations, covering key lysosomal ion channels, transporters and enzymes, such as TMEM175, TPC2, TRPML1, GBA1, and others. ORIA offers lysosomes from endogenous, knockout and overexpression cell lines, as well as custom client-specific cell lines on demand. This allows customers to select the biological context best suited to their screening campaign.
Each preparation is validated for functional readouts and is directly compatible with a wide range of applications. Combined with modern high-content platforms, it enables over 500 measurement points per hour. In short, LYSO-Prep™ brings together everything the field has been waiting for: industrial scale, biological fidelity, HTS compatibility, and true ready-to-use simplicity.
This expanded target and cell-line diversity gives pharmaceutical teams unprecedented flexibility to interrogate lysosomal biology across neurodegeneration, lysosomal storage disorders, oncology, and metabolic disease, with the relevance, precision, and reproducibility that successful drug discovery decisions demand, without the variability and delays of in-house lysosome extraction.
PAIA Biotech GmbH | FcRn binding assay kit | Booth 510
https://www.paiabio.com/fcrn-binding
We are presenting a new assay based on the PAIA microplate technology. It is an addition to the existing portfolio of high throughput developability assays by PAIA and allows for the detection of the pH-dependent binding and release of antibodies to the FcRn receptor in a simple and entirely microplate-based workflow.
This receptor is crucial for the intracellular recycling of antibodies and a main determinant of antibody clearance. The assay measures the binding to immobilized FcRn at four different pH levels in separate wells and only small amounts of sample (1µg of protein).
The assay results is a desorption curve which allows for the determination of the pH at which the antibodies are released from the receptor. Ideal molecules show strong binding at acidic pH levels and no binding at neutral pH, which guarantees efficient recycling.
This is the first assay to provide this type of critical data on the FcRn interaction and is considered a replacement of FcRn chromatography which is costly and a factor of 100 slower.
PharmaBlock | PharmaBlock-5615 | Booth 502
https://www.pharmablock.com/
"ZoeStar™: Accelerating Discovery of Next-Generation Therapies with AI and intelligent Chemistry
ZoeStar™ is PharmaBlock's next-generation AI-powered drug discovery platform, designed to accelerate the discovery of small molecules and emerging modalities including peptides, oligonucleotides, ADCs, DACs, AOCs, molecular glues, and targeted protein degraders.
Unlike conventional AI approaches that stop at molecular design, ZoeStar™, built on PharmaBlock's unique chemistry ecosystem, integrates proprietary AI models, DNA-Encoded Library (DEL) technologies, fragment-based discovery, virtual screening, medicinal chemistry expertise, and more than 200,000 structurally diverse building blocks into a seamless end-to-end discovery platform directly connected to real-world synthesis and experimental validation. The platform leverages PharmaBlock's extensive collections of novel CRBN ligands, linker-payload systems, unnatural amino acids, peptide building blocks, phosphoramidites, GalNAc conjugation components, and other specialty reagents to enable rapid design-make-test-learn cycles across diverse therapeutic modalities.
By integrating AI-driven hit generation, lead optimization, ADMET prediction, and synthesis-ready chemical space, ZoeStar™ transforms scientific complexity into therapeutic opportunity. The result is faster discovery, better-quality leads, and increased confidence in advancing next-generation therapeutics from concept to candidate.
Where AI Meets Chemistry. Where Next-Generation Therapies Begin.
PozeSCAF Discovery Solutions | AxDrug™ | Booth 401
https://pozescaf.com/axdrug-ai-computational-chemistry-platform/
AxDrug™ - From Disease Biology to Differentiated Drug Candidates
AxDrug™, PozeSCAF’s integrated AI- and physics-driven drug discovery platform, unifies disease biology, target intelligence, generative chemistry, molecular simulation, medicinal chemistry, synthesis, and experimental validation to accelerate discovery and reduce experimental iterations.
Target & Proximal Glue-Pair Identification:
KG-SCAF integrates genetic, pathway, expression, PPI, chemical, structural, and literature evidence to identify disease-relevant targets, proximal protein partners, glue-compatible pairs, synthetic-lethal relationships, and disease-specific interaction networks. Protein dynamics and cryptic-pocket sampling identify dynamic glue pockets, transient binding sites, allosteric pockets, and ligandable interfaces.
Target-Specific Ligand, Peptide & Molecular-Glue Discovery:
RG-SCAF enables structure-conditioned generation of small molecules, linear/cyclic peptides, and molecular glues, combined with screening of 100M+ drug-like molecules and ~6M glue-focused compounds, supported by 200+ ADMET and 360+ off-target models. Physics-based prioritization advances validated pockets toward prioritized hit series in ~10–12 weeks, with covalent programs evaluating reversible and irreversible binding.
Integrated Discovery & Optimization:
AxDrug integrates MDS, water thermodynamics, binding-energy calculations, FEP/RBFE, medicinal chemistry, retrosynthesis, synthesis, and biology in a continuous Design → Predict → Validate → Make → Test → Learn cycle. Across 30+ challenging targets, AxDrug has generated experimentally actionable candidate series, with selected programs advancing ~200 compounds/target for robust SAR and proof-of-concept. For validated biology and established workflows, the platform is designed to support IND-enabling candidates in ~18 months.
Sino Biological US | Recombinant Human Tau Protein, T217 Phosphorylated (T08-50SN) | Booth 208
https://www.sinobiological.com/category/protein/p-tau217-protein-t08-50sn
Brief Product Description & Technical Specifications:
Sino Biological Inc. announces the launch of its Recombinant Human p-Tau217 Protein (Cat. No. T08-50SN), a full-length, tag-free Tau reagent developed to support Alzheimer’s disease biomarker assay development, antibody evaluation, and Tau biology research. This new product expands Sino Biological’s comprehensive Tau protein portfolio, supporting advance neurodegenerative disease research.
Defined Phosphorylation Profile:
p-Tau217 is an emerging biomarker associated with amyloid pathology and Alzheimer’s disease, creating demand for well-characterized reagents for plasma- and CSF-based assay development. Sino Biological’s human p-Tau217 protein provides complete protein context for biomarker assays and antibody evaluation while helping avoid potential tag-related effects on target recognition or assay performance.
The protein is generated through a proprietary enzymatic process designed to enrich phosphorylation at Thr217 while maintaining the clinically relevant Thr181 and Thr231 sites in an unphosphorylated state. Mass spectrometry confirms a high level of phosphorylation at Thr217, while no phosphorylation is detected at Thr181 or Thr231. Independent Western blot analysis provides orthogonal confirmation of this phosphorylation profile. This defined characterization helps researchers reduce potential confounding from off-target phospho-site recognition when evaluating p-Tau217 antibodies and assay performance.
Applications in Alzheimer’s Research:
With its full-length, tag-free format and precisely defined phosphorylation profile, the p-Tau217 protein supports a wide range of applications, including plasma- and CSF-based Alzheimer’s biomarker assay development, antibody screening and specificity validation, assay control optimization, and mechanistic studies on Tau phosphorylation and neurodegeneration.
Sygnature Discovery | Direct-to-Crystal (D2C), Version Number 1 | Booth 418
https://www.sygnaturediscovery.com/
As drug discovery targets grow in complexity and novelty, one of the greatest challenges is validating high-quality chemical starting points. Hits can now emerge from diverse sources, yet building confidence in a chemical series still demands extensive hit expansion which is slow, resource intensive, and expensive.
Direct-to-Biology (D2B) transforms this early phase by enabling rapid generation of biological data directly from crude reaction mixtures, accelerating decisions and reducing cost. While D2B provides critical binding data, it does not reveal how ligands engage their targets. Structural insight remains essential, particularly in FBDD, where understanding ligand–protein interactions is fundamental.
To meet this need, we developed a Direct-to-Crystal (D2C) service, built on deep expertise in protein production and structural biology and supported by automated workflows. D2C generates ligand-bound crystal structures directly from crude mixtures and integrates seamlessly with D2B, high-throughput experimentation, and high-throughput chemistry to create a powerful, end-to-end platform for rapid hit expansion and optimisation.
This approach is already delivering impact. For STORM Therapeutics, our multidisciplinary team supported a highly accelerated discovery campaign, progressing their DHX9 inhibitor programme from lead to precandidate nomination in just 18 months, well ahead of industry timelines. STORM described Sygnature as “an extension of our in-house team… responding fearlessly to ambitious timelines.” Four D2B production runs contributed to this speed, enabling rapid biological confirmation of emerging chemical matter, while integrated structural insight supported fast, confident optimisation.
Together, D2B and D2C show how connected science, automation, and structural insight can accelerate discovery and drive real impact.
TubeWriter, LLC | TubeWriter 400 (Software v52 Upgrade — August 2026) | Booth 211
https://www.tubewriter.com
The TubeWriter 400 is a benchtop, direct-to-tube laboratory printer that permanently marks sample tubes, vials, plates, and cryogenic labware with high-resolution alphanumerics, barcodes, and 2D codes — eliminating hand-labeling errors and label loss in cold storage, autoclaves, and organic solvent workflows. Its August 2026 Software v5.2 release delivers native barcode/2D-code integration, expanded worklist import from LIMS and ELN platforms, and streamlined batch-print workflows built directly from lab-user feedback. Durability is the #1 differentiator. Unlike adhesive labels that curl, peel, or fall off during freezer storage, autoclaving, or solvent exposure, TubeWriter's markings are permanent — engineered to survive the full sample lifecycle from prep to long-term biobanking. This eliminates chain-of-custody breaks and the costly rework that comes with unreadable samples. The upgraded software also strengthens integration with existing lab infrastructure, making it easier for cell & gene therapy, bioprocessing, and discovery labs to trace samples across teams, sites, and studies without introducing new points of failure. For labs scaling sample volumes or preparing for regulated environments, TubeWriter 400 v52 turns sample identification from a chronic risk into a durable, auditable step in every workflow. Key benefits: Permanent markings · LIMS/ELN-ready · Cryo & autoclave-safe · Barcode/2D native · Chain-of-custody assured.
X-Chem, Inc. | DELvantage | Booth 304
https://www.x-chemrx.com
The hardest decisions come after the screen. DEL screening generates thousands of potential hits and families, but teams still need to determine what to pursue, which compounds to synthesize, and where to invest chemistry resources next.
DELvantage extends DEL-derived SAR beyond enriched hits, combining positive and negative screening data with three-dimensional, pharmacophore-guided analysis to inform compound prioritization and design. Developed by X-Chem, DELvantage uses the full dataset, including what enriched, what did not, and what falls in between, to reveal SAR patterns that can be missed when evaluating enriched hits alone.
DELvantage has been demonstrated in the TBXT Challenge led by the Chordoma Foundation, where ML and computational chemistry were used to identify and prioritize compounds for experimental follow-up. Of 20 purchased compounds, 12 were confirmed binders, demonstrating how chemomics can transform large-scale DEL datasets into actionable, experimentally validated starting points.
DELvantage helps reduce uncertainty before the time, cost, and risk of off-DNA synthesis, and gives historical DEL datasets a second life, including programs without previously confirmed hits.